Tuesday, 25 Jul 2017

You are here

New insights into the impact of pegloticase in chronic refractory gout

Pegloticase is indicated for treatment of patients with refractory gout. One major issue hampering the comfort levels of rheumatologists to use this agent is the boxed warning in the package insert regarding the documentation of anaphylaxis with the infusions. It is well known that treatment with pegloticase is associated with the development of anti-drug antibodies, which are believed to belie these reactions. 

Abstract THU0438 by Drs. Calabrese, Kavanaugh, Yeo, and Lipsky is a study taking a deep dive into all the infusion reactions encountered during the pegloticase trials where each reaction was adjudicated post hoc and the relationship to whether the patients continued to have their uric acid suppressed (a surrogate of lack of antidrug antibodies) or whether they were failing (a surrogate for the presence of anti-drug antibodies) was explored. The NIAID/FAAN criteria were used to classify infusion reactions. 

The bottom and surprising line is that in the cohort receiving pegloticase q 2 weeks (as recommended in the PI) and who maintained uric acid suppression (i.e., the way we do in clinical practice) the rate of infusion reactions of any kind was 0.5% or 1 in 200 infusions. Furthermore, in this group there were no cases of anaphylaxis.

Lastly, among the 6 cases of ‘anaphylaxis’ among the over 1600 infusions none were fatal or even serious (i.e., requiring advanced support) and 3 of the patients stayed in the trial. It appears that when pegloticase is used correctly it has an excellent safety profile and these data should be reassuring. 

 

L Calabrese, A. Kavanaugh, A Yeo, P Lipsky
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Pharma Pays $8.2 Billion to Physicians in 2016

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

The RheumNow Week in Review – 30 June 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.